Loading clinical trials...
Loading clinical trials...
Phase 1, Placebo-controlled, Randomized, Sequential, Parallel-group, Dose Escalation Study to Evaluate 28-day Multiple Dose Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CP-690,550 in Stable Renal Allograft Recipients
Conditions
Interventions
Placebo
CP-690,550 5 mg BID
+2 more
Locations
11
United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Indianapolis, Indiana, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Start Date
September 1, 2003
Primary Completion Date
April 1, 2005
Completion Date
April 1, 2005
Last Updated
December 26, 2012
NCT05702398
NCT07415421
NCT07006532
NCT07333495
NCT04542733
NCT06958796
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions